biotech · Blepharitis · Meibomian Gland Dysfunction · TARS
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a biotech organization headquartered in Irvine, USA. It trades on NYSE under ticker TARS. Primary therapeutic focus areas include Blepharitis, Meibomian Gland Dysfunction, Papulopustular Rosacea
15440 Laguna Canyon Rd, Irvine, California 92618, US HQ
2017 Founded
403 Employees
Public company Type
TARS · NYSE Ticker
Company details
- Status
- Public
- HQ
- 15440 Laguna Canyon Rd, Irvine, California 92618, US
- Founded
- 2017
- Employees
- 403
- Programs
- 14
- Drugs
- 10
- Patents
- 9
TP-03
Phase 2 · small molecule · Meibomian Gland Dysfunction
TP-03 for Meibomian Gland Dysfunction is a Phase 2 program (small_molecule) at Tarsus Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code TRS-008
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Tarsus Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Meibomian Gland Dysfunction
- Status
- completed
- Trials
- 1